Prostate Cancer

An analysis from the ARASENS trial showed that the addition of darolutamide (Nubeqa) to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high-volume and high-risk disease and should be considered the new standard of care for this patient population. Read More ›

The addition of the PARP inhibitor niraparib (Zejula) to abiraterone acetate (Zytiga) plus prednisone (AAP) led to a significant improvement in radiographic progression-free survival (PFS) versus AAP alone in men with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations, according to the final analysis of the primary end point of a phase 3 trial. Read More ›

Two years of abiraterone acetate (Zytiga) plus prednisone added to androgen-deprivation therapy (ADT) improved metastasis-free survival and overall survival compared with ADT alone in men with nonme­tastatic castration-­sensitive prostate cancer, whereas the addition of enzalutamide (Xtandi) to ADT had no benefit, and much greater toxicity. Read More ›

Preliminary results from the first prospective study of a genomic classifier for African-American men suggest that both disparities in access to care and biological factors may be responsible for the increased incidence and mortality in this patient population. The study also identified a significant age difference between African-American and non–African-American men with respect to high genomic risk. These findings were presented during the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

Cabazitaxel (Jevtana) is approved as third-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC) after treatment with docetaxel and an androgen receptor inhibitor. A new phase 2 clinical trial shows that the radionuclide therapy that targets the prostate-specific membrane antigen (PSMA), ¹⁷⁷Lu-PSMA-617, reduced the risk for disease progression or death by 37% compared with cabazitaxel in men with previously treated metastatic CRPC. Moreover, the TheraP study showed that patients who received ¹⁷⁷Lu-PSMA-617 had fewer side effects and improved quality of life compared with patients who received cabazitaxel. Read More ›

Rucaparib (Rubraca, Clovis Oncology) demonstrated promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration, according to results of a study published online in the Journal of Clinical Oncology. Read More ›

Black men with low-risk prostate cancer who were on active surveillance had an increased risk for disease progression and definitive treatment compared with their non-Hispanic White counterparts, but not increased mortality, according to the results of a recent study. Read More ›

Oral relugolix given daily is superior to standard androgen-deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting (Shore ND, et al. N Engl J Med. 2020;382:2187-2196). Read More ›

arly results from the phase 2 TheraP clinical trial show that the targeted radiation therapy ¹⁷⁷Lutetium PSMA-617 (Lu-PSMA) significantly improved prostate-specific antigen (PSA) response compared with standard cabazitaxel in men with metastatic castration-resistant prostate cancer (CRPC) that progressed after docetaxel therapy. Read More ›